摘要
目的:探讨德谷门冬双胰岛素联合非诺贝特对肥胖型2型糖尿病患者内脏脂肪指数的影响。方法:选取2022年9月—2023年9月平煤神马医疗集团总医院收治的136例肥胖型2型糖尿病患者作为研究对象,按照随机数表法将其分为对照组(68例)和观察组(68例)。两组患者均采用常规运动、饮食控制,对照组给予德谷门冬双胰岛素联合辛伐他汀治疗,观察组给予德谷门冬双胰岛素联合非诺贝特治疗,两组患者均持续治疗1个月。比较两组患者糖脂代谢指标、胰岛素相关指标、内脏脂肪指数,并统计两组患者治疗期间不良反应发生情况。结果:治疗1个月时,观察组患者总胆固醇、糖化血红蛋白、低密度脂蛋白胆固醇、餐后2 h血糖、甘油三酯、空腹血糖水平均低于对照组,高密度脂蛋白胆固醇水平均高于对照组,差异均有统计学意义(t=4.866、2.392、2.559、3.130、4.059、6.397、2.698,P<0.05);观察组患者胰岛素抵抗指数高于对照组,胰高血糖素样肽-1、空腹胰岛素水平均低于对照组,差异均有统计学意义(t=8.173、6.864、8.947,P<0.05);两组患者的内脏脂肪指数均低于治疗前,且观察组低于对照组,差异均有统计学意义(t=6.144、3.317、3.308,P<0.05)。结论:德谷门冬双胰岛素联合非诺贝特可改善肥胖型2型糖尿病患者糖脂代谢指标和胰岛素相关指标,降低患者内脏脂肪指数,且不会增加不良反应。
Objective:To investigate the effect of insulin degludec/insulin aspart combined with fenofibrate on visceral fat index in obese type 2 diabetes patients.Methods:136 obese type 2 diabetes patients admitted to the hospital from September 2022 to September 2023 were divided into the control group(68 cases)and the observation group(68 cases)according to the random number table method.Both groups received routine exercise and dietary control.The control group received treatment with insulin degludec/insulin aspart combined with simvastatin,while the observation group received treatment with insulin degludec/insulin aspart combined with fenofibrate、The treatment lasted for 1 month.The indexes of glucose and lipid metabolism,insulin related indexes and visceral fat index were compared between the two groups,and the incidence of adverse reactions during treatment was counted.Results:1 month after treatment,the levels of total cholesterol,glycated hemoglobin,low-density lipoprotein cholesterol,2-hour postprandial blood glucose,triglycerides and fasting blood glucose in the observation group were all lower than those in the control group,while the level of high-density lipoprotein cholesterol was higher than that in the control group.The differences were all statistically significant(t=4.866,2.392,2.559,3.130,4.059,6.397,2.698;P<0.05).The insulin resistance index level of patients in the observation group was higher than that in the control group,while the glucagon-like peptide-1 and fasting insulin levels were lower than those in the control group.The differences were statistically significant(t=8.173,6.864,8.947;P<0.05).The visceral fat index of both groups of patients was lower than that before treatment,and the index of the observation group was lower than that of the control group.The difference was statistically significant(t=6.144,3.317,3.308;P<0.05).Conclusion:Insulin degludec/insulin aspart combined with fenofibrate can improve the glucose and lipid metabolism indexes and insulin related indexes in obese type 2 diabetes patients,reduce the visceral fat index of patients,and will not increase adverse reactions.
作者
刘晓龙
杜佳
Liu Xiaolong;Du Jia(Pharmaceutical Dispensing Department,General Hospital of Pingmei Shenma Group,Pingdingshan,Henan,467000,China)
出处
《黑龙江医学》
2025年第14期1735-1737,1741,共4页
Heilongjiang Medical Journal
